Background
Methods
Search strategy and selection criteria
Quality assessment
Results
Quality assessment
Study | Prospective | Multi-centre | PET scanners used | EANM guidelines stated | SUV defined | Definition of prognostic factor provide | Follow up period | Separate validation cohort | Overall risk of bias |
---|---|---|---|---|---|---|---|---|---|
Adams [9] | N | N | Siemens Biograph 40 TruePoint | N | N | PFS - relapse/progression/death attributable to PFS OS - Death from any cause | Median: 994 days | N | Moderate |
Aide [10] | N | N | Siemens Biograph TrueV | N | N | EFS - relapse/progression/unplanned treatment/death attributable to PFS | 2-year EFS | Y | High |
Aide [11] | N | N | Siemens Biograph TrueV | Y | N | PFS - relapse/progression OS - death from lymphoma or treatment | Median: 25.7 months | N | Moderate |
Akhtari [12] | N | N | GE Discovery ST GE Discovery RX GE Discovery STE | N | Y(bw) | FFP - relapse or refractory disease OS - death from any cause | Median: 4.96 years | N | Moderate |
Albano [13] | N | Y | GE Discovery ST GE Discovery 690 | Y | N | PFS - progression/relapse/death OS - death from any cause | Median: 40 months | N | Moderate |
Angelopulou [14] | N | N | Multiple not defined | N | N | FFP - relapse or refractory disease OS - death from any cause | Median: 56 months | N | High |
Capobianco [15] | N | Y | Multiple1 | N | N | Not defined | Median: 5 years | Y | High |
Ceriani [16] | N | Y | Multiple not defined | N | N | Not defined | Median: 64 months, 34 months | Y | High |
Chang [17] | N | N | GE Discovery ST | N | N | PFS - progression/relapse/death OS - death from any cause | Median: 28.7 months | N | Moderate |
Chang [18] | N | N | GE Discovery ST | N | N | PFS - progression/relapse/death OS - death from any cause | median 36 months | N | Moderate |
Chihara [19] | N | N | GE Discovery LS | N | Y(bw) | PFS - progression/relapse/death from any cause OS - death from any cause | Median: 34.4 months | N | Moderate |
Cottereau [20] | N | Y | Multiple not defined | N | N | Not defined | Median: 44 months | N | High |
Cottereau [21] | N | Y | Multiple not defined | N | N | PFS - progression/death from any cause OS - death from any cause | Median: 55 months | Y | Moderate |
Cottereau [22] | N | N | Siemens Biograph 16 | N | N | OS and PFS were defined according to the revised NCI criteria | Median: 64 months | N | Moderate |
Decazes [23] | N | N | Siemens Biograph Sensation 16 HiRes | N | N | Both OS and PFS were defined according to the revised NCI criteria | Median: 44 months | N | Moderate |
Esfahani [24] | N | N | Siemens Biograph | N | N | PFS - recurrence | Mean: 51 months | N | High |
Gallicchio [25] | N | N | GE Discovery VCT GE Discovery LS VCT | N | N | Progression/disease-related death | Median: 18 months | N | High |
Huang [26] | N | N | GE Discovery LS | N | Y(bw) | PFS - progression/relapse/death OS - death from any cause | Median: 30 months | N | Moderate |
Ilyas [27] | N | N | GE Discovery ST GE Discovery VCT | N | N | PFS - progression/death from any cause OS - death from any cause | Median: 3.8 years | N | High |
Jegadesh [28] | N | N | Not defined | N | N | Not defined | Median: 43.9 months | N | Moderate |
Kanoun [29] | N | N | Philips Gemini GXL Philips Gemini TOF | N | N | PFS - progression/relapse/death from any cause | Median: 50 months | N | High |
Kim [30] | N | N | Siemens Biograph 6 | N | N | EFS - relapse/progression/stopping of treatment/death from any cause OS - death from any cause | Median: 27.8 months | N | Moderate |
Kim [31] | N | N | Philips Gemini Siemens Biograph 40 | N | N | PFS - progression/relapse/death OS - death (? any cause) | Median: 25.8 months | N | Moderate |
Kwon [32] | N | Y | GE Discovery ST | N | Y(bw) | PFS - progression/relapse/death from any cause OS - death from any cause | Median: 30.8 months | N | High |
Lanic [33] | N | Y | Siemens Biograph LSO Sensation 16 | N | N | PFS - progression/relapse/death from any cause OS - death from any cause | Median: 28 months | N | High |
Lue [34] | N | N | GE Discovery ST | N | N | PFS - progression/relapse/death from any cause OS - death from any cause | Median: 48 months | N | Moderate |
Mettler [35] | N | Y | Multiple not defined | N | N | PFS - progression/relapse/death from any cause OS - death from any cause | Not defined | N | High |
Mikhaeel [36] | N | N | GE Discovery ST GE Discovery VCT | N | N | PFS - progression/death from any cause OS - death | Median: 3.8 years | N | Moderate |
Milgrom [37] | N | N | GE Discovery ST GE Discovery RX GE Discovery STE | N | N | Relapse or progression or death | Not defined | Y | High |
Miyazaki [38] | N | N | GE Discovery STE | N | N | PFS - relapse/death from any cause OS - death | Median: 32.7 months | N | Moderate |
Park [39] | N | N | GE Discovery LS, GE Discovery STE | N | N | PFS - progression/relapse/death from any cause OS - death from any cause | Median: 21 months | N | High |
Sasanelli [40] | N | Y | Philips Gemini GXL Siemens Biograph 2 GE Discovery ST | N | Y(bw) | PFS - relapse OS - death from any cause | Median: 39 months | N | Moderate |
Senjo [41] | N | Y | Philips Gemini GXL GE Discovery ST | Y | Y(bw) | PFS - progression/relapse/death OS - death | Median: 33.1 months, 32.8 months | Y | High |
Song [42] | N | Y | Siemens Biograph | N | N | PFS progression OS - death from any cause | Median: 40.8 months | Y | Moderate |
Song [43] | N | Y | Siemens Biograph | N | N | Not defined | Median: 45.8 months | N | Moderate |
Song [44] | N | Y | Siemens Biograph | N | N | PFS progression, death related to lymphoma OS - death from any cause | Median: 36 months | N | Moderate |
Toledano [45] | N | N | Siemens Biograph Sensation 16 HiRes | N | N | OS and PFS were defined according to the revised NCI criteria | Median: 40 months | N | Moderate |
Tseng [46] | N | N | GE Discovery LS | N | N | Not defined | Median: 50 months | N | High |
Xie [47] | N | N | Siemens Biograph 64 | Y | N | PFS - progression/relapse/death from any cause | Median: 17 months | N | High |
Zhang [48] | N | N | Siemens Biograph 64 | N | N | PFS - progression, death related to lymphoma | Median: 34 months | N | Moderate |
Zhou [49] | N | N | GE Discovery ST Siemens Biograph 64 | N | N | N - not defined | Median: 30 months | N | Moderate |
Metabolic parameters
SUV metrics for prediction of outcome
First author | Year | Type | Study type | Patient no. | Stage | Treatment | Events (follow-up cut-off) | SUV Type | Cut-off value | Predictive univariate analysis HR (95% CI) | Predictive multivariate analysis HR (95% CI), parameters included in multivariate analysis | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
I/II | III/IV | PFS | OS | PFS | OS | |||||||||
Aide [10] | 2020 | DLBCL | R | 132 (80:20 training/validation) | NR | NR | R-CHOP, R-ACVBP | Relapse/death: 102 (2-year) | SUVmax | 32.21 | NS | NR | NR | NR |
Albano [13]a | 2020 | HL (Aged 65–92) | R | 123 | 36 | 87 | ABVD, BEACOPP, R-CHOP, ± RT, RT | Relapse: 51 Died: 37 (no defined cut-off) | L-L SUV R | 9.3 | 0.447 (0.237–0.748) | 0.526 (0.261–0.992) | 0.228 (0.049–0.765) | 0.200 (0.033–0.353) |
L-BP SUV R | 6.4 | 0.469 (0.229–0.774) | 0.523 (0.241–0.983) | 0.354 (0.069–0.989) | 0.555 (0.201–1.002) | |||||||||
Ceriani [16] | 2020 | DLBCL | R | 141 – Testing | 61 | 80 | R-CHOP ± RT | NR | Max | 20 | NS | NS | NR | NR |
113 -Validation | 49 | 64 | R-CHOP ± RT | NR | Max | 31 | NS | NS | NR | NR | ||||
Zhang [48] | 2019 | DLBCL | R | 85 | 32 | 53 | R-CHOP/R-CHOP like | Relapse/Died:23 (3-year) | Max | NR – AUC 0.573 | NR | NR | NR | NR |
Akhtari [12] | 2018 | HL | R | 267 | 205 | 62 | ABVD ± RT/othera | Relapsed/refractory: 27 (5-year) | Max | NR | NS | NR | NR | NR |
Cottereau [21] | 2018 | HL | R | 258 | 258 | 0 | ABVD ± RT | PFS: 27 events OS: 12 (5-year) | Max | NR | NS | NS | NR | NR |
Toledano [45] | 2018 | DLBCL | R | 114 | 26 | 88 | R-CHOP/R-CHOP like | Relapse: 52 Died: 43 (5-year) | Max | NR | NS | NS | NR | NR |
Angelopoulou [14] | 2017 | HL | R | 162 | 76 | 86 | ABVD ± BEACOPP, ± RT | PFS: 81% OS: 93% (5-year) | Max | <9, 9–18, >18 | 93%, 81%, 58% | NR | NR | NR |
Chang [17] | 2017 | DLBCL | R | 118 | 48 | 70 | R-CHOP | Relapse: 55 Died: 49 (5-year) | Max | 18.8 | NS | NS | NR | NR |
Chang [18] | 2017 | DLBCL | R | 70 | 35 | 35 | R-CHOP | NR | Tumour Max | 19 | 2.76 (1.05–7.61) | NS | 3.27 (1.11–9.60) | NS |
Sternal Max | 1.6 | NS | 2.34 (1.01–5.44) | NS | 2.62 (1.10–6.28 | |||||||||
Cottereau [22] | 2016 | DLBCL | R | 81 | 16 | 65 | R-CHOP, R-ACVBP | Relapse: 34 (5-year) | Max | NR | NS | NS | NR | NR |
Huang [26] | 2016 | DLBCL | R | 140 | 62 | 78 | R-CHOP/CHOP | PFS: 73.8% OS: 86.1% (30-month) | Max | 9 | 7.2 (2.201–23.631) | 11.4 (1.514–86.350 0.018) | 4.7 (1.429–16.022 0.011) | NS |
Mikhaeel [36] | 2016 | DLBCL | R | 147 | 46 | 101 | R-CHOP | PFS: 65.4% OS: 73.7% (5-year) | Max | Split into tertiles | NS | NS | NR | NR |
Xie [47] | 2016 | DLBCL | R | 60 | 12 | 48 | R-CHOP | Relapse: 17 Died: 3 (40-month) | Max | NR | NS | NR | NS | NR |
Zhou [49] | 2016 | DLBCL | R | 91 | 34 | 57 | R-CHOP | Relapse: 37 Died: 11 (5-year) | Max | PFS – 19 OS – 15.8 | NS | NS | NR | NR |
Adams [9] | 2015 | DLBCL | R | 73 | 11 | 62 | R-CHOP | Relapse: 27 Death: 24 (No defined cut-off) | Max | NR | NS | NS | NR | NR |
Jagadeesh [28] | 2015 | DLBCL | R | 89 | 0 | 89 | R-CHOP/R + other | LR: 50% (5-year) | Max | 15 | NS for LR | NR | NS for LR | NR |
Kwon [32] | 2015 | DLBCL | R | 92 | 54 | 38 | R-CHOP | Relapse: 33 Died: 3 (No defined cut-off) | Max | 10.5 | 4.31 (1.03–18.1) | NR | NS | NR |
Gallicchio [25] | 2014 | DLBCL | R | 52 | 26 | 26 | R-CHOP, R-COMP | Relapse: 15 Died: 2 (18 month) | Max | 13.5 | 0.13 (0.04–0.46) | NR | NR | NR |
Esfahani [24] | 2013 | DLBCL | R | 20 | 8 | 12 | R-CHOP | Relapse: 6 (No defined cut-off) | Max | 13.84 | NS | NR | NR | NR |
Mean | 6.44 | NS | NR | NR | NR | |||||||||
Kim [31] | 2013 | DLBCL | R | 140 | 77 | 63 | R-CHOP | Relapse: 21 Died: 16 (2-year) | Max | 16.4 | NS | NS | NR | NR |
Lanic [33] | 2012 | DLBCL | R | 57 | NR | NR | R-CHOP, intensified R-CHOP | NR (2-year) | Max | NR | NS | NS | NR | NR |
Park [39] | 2012 | DLBCL | R | 100 | 55 | 45 | R-CHOP | NR | Max | NR | NS | NS | NR | NR |
Sum | NR | 1.011 (1.002–1.020) | 1.016 (1.006–1.026) | NR | NR | |||||||||
Tseng [46] | 2012 | HL | R | 30 | 11 | 19 | Standford V, ABVD, VAMP, BEACOPP | Relapse =6 (4-year) | Max | NR | NS | NS | NR | NR |
Mean | NR | NS | NS | NR | NR | |||||||||
Chihara [19] | 2011 | DLBCL | R | 110 | 65 | 45 | R-CHOP ± RT | PFS: 75% OS: 84% (3-year) | Max | 30 | Sig. | Sig. | HR6.74 | NS |
Metabolic tumour volume and total lesion glycolysis for prediction of outcome
Author | Year | Patient no. | Stage | Treatment | Events (follow-up cut-off) | Segmentation threshold | MTV/ TLG | Suggested cut-off | Predictive univariate analysis HR (95% CI) | Predictive multivariate analysis HR (95% CI), parameters included in multivariate analysis | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
I/II | III/IV | PFS | OS | PFS | OS | ||||||||
Aide [10] | 2020 | 132 | NR | NR | R-CHOP, R-ACVBP | Relapse/death: 102 (2-year) | SUVmax of liver | MTV | 111 ml | 10.2 (1.4–75.5) (training data set) NS (Validation dataset) | NR | NS aa-IPI LZHGE | NR |
Capobianco [15] | 2020 | 280 | 26 | 264 | R-CHOP | Relapse: 86 Died: 51 (4-year) | 41% SUVmax | MTV | 242 ml | NR | 3.7 (1.9–7.2) | NR | NR |
CNN segmentation | MTV | 110 ml | NR | 2.8 (1.6–5.1) | NR | NR | |||||||
Decazes [23] | 2018 | 215 | 51 | 164 | R-CHOP, R-CHOP like, R-ACVBP | Relapse: 92 Died: 74 (5-year) | 41% SUVmax | MTV | 487 ml | 3.10(1.95–4.95) | 4.09(2.32–7.21) | 2.20 (1.26–3.83) IPI, chemotherapy, TVSR | 2.78(1.41–5.48) IPI, chemotherapy, TVSR |
Ilyas [27] | 2018 | 147 | 46 | 101 | R-CHOP | PFS: 65.4% OS: 73.7% (5-year) | PETTRA 2.5 | MTV | PFS:396.1 ml OS: 457.8 ml | 5.9 (2.9–12.2) | 5.5 (2.4–12.5) | NR | NR |
HERMES 2.5 | MTV | PFS:401.4 ml OS: 401.4 ml | 5.9 (2.9–12.2 CI) | 5.5 (2.4– 12.5) | NR | NR | |||||||
HERMES PERCIST | MTV | PFS:327.4 ml OS: 669.8 ml | 4.8 (2.4–9.5 CI) | 3.7 (1.8–7.8) | NR | NR | |||||||
HERMES 41% | MTV | PFS:165.7 ml OS: 189.3 ml | 4.2 (2.2–7.9 CI) for | 3.5 (1.8–7.0) | NR | NR | |||||||
Senjo [41] | 2019 | 150 (combined training and validation) | 66 | 84 | R-CHOP, R-THP-COP, R-CVP | Relapse 21 Died 48 (5-year) | >4.0 SUV | MTV | 150 ml | NR | NR | 2.49 (1.57–3.94) | 2.75 (1.72–4.38) |
Zhang [48] | 2019 | 85 | 32 | 53 | R-CHOP/R-CHOP-like | Relapse: 23 Died: 6 (3-years) | MTV | 80.74 ml | 10.32 (2.42–44.08) | NR | NR Correlated with TLG | NR | |
TLG | 1036.61 g | 10.39 (2.43–44.39) | NR | 10.42, (2.35–46.30) | NR | ||||||||
Toledano [45] | 2018 | 114 | 26 | 88 | R-CHOP/R-CHOP like | Relapse: 52 Died: 43 (5-year) | 41% SUVmax | MTV | 261.4 ml | 2.91 (1.60–5.29) | 4.32 (2.07–8.99) | 2.05 (HR 1.02–4.15) GEP, IPI | 2.70 (1.16–6.33) GEP, IPI |
TLG | 1325.8 g | NS MC | 4.82 (2.67–8.71) | NR | NR | ||||||||
Chang [17] | 2017 | 118 | 48 | 70 | R-CHOP | Relapse: 55 Died: 49 (5-year) | ≥2.5 SUV | MTV | 165.4 ml | 3.32 (1.78–6.20) | 4.05 (2.07–7.95) | 2.31 (1.16–4.60) IPI | 2.38 (1.12–5.04) Age, IPI |
TLG | 1204.9 ml | 2.57 (1.43–4.61) | 2.96 (1.61–5.45) | NR | NR | ||||||||
Cottereau [22] | 2016 | 81 | 16 | 65 | R-CHOP, R-ACVBP | Relapse: 34 (5-year) | 41% SUVmax | MTV | 300 ml | 3.06 (1.43–6.54) | 3.01 (1.35–6.70) | 1.61 (0.70–3.69) | 3.0 (1.35–6.70) |
TLG | 3904 g | 2.92 (1.45–5.90) | 2.39 (1.16–4.92) | NS | NS | ||||||||
Song [42] | 2016 | 107* | 107 | R-CHOP | NR | ≥2.5 SUV | MTV | 601.2 ml | Sig. | Sig. | 5.21 (2.54–10.69) IPI, bulky disease, BMI, IM MTV, CAs | 5.33 (2.60–10.90) IPI, bulky disease, BMI, IM MTV, CAs | |
IM MTV | 260.5 ml | Significant | Significant | NS | NS | ||||||||
Zhou [49] | 2016 | 91 | 34 | 57 | R-CHOP | Relapse: 37 Died: 11 (5-year) | SUVmean of liver +3 SD | MTV | PFS: 70 ml OS: 78 ml | 88 vs. 37% | 98 vs. 60% | NS | NS |
TLG | PFS: 826.5 g OS: 726 g | 83 vs. 34% | 92 vs. 67% | 5.21 (2.21–12.28) MTV, NCCN-IPI, Stage, B symptoms, LDH level Ki-67 | 9.1 (1.83–45.64) MTV, NCCN-IPI, Stage, B symptoms, LDH level Ki-67 | ||||||||
Mikhaeel [36] | 2016 | 147 | 46 | 101 | R-CHOP | PFS5: 65.4% OS5: 73.7% (5-year) | 41% SUVmax | MTV | Terties | Upper: 5.81 (2.38–14.14) Middle: 3.77 (1.49–9.51) | Sig. | Upper: 3.46 (1.10–10.86) Middle: 2.73 (0.89–8.40) | NR |
TLG | Tertiles | Upper: 4.90 (2.11- 11.38) Middle: (2.96 1.24 7.10) | Sig. | NR | NR | ||||||||
Xie [47] | 2016 | 60 | 12 | 48 | R-CHOP | Relapse: 17 Died: 3 (40 months) | SUVmean of liver +2SD | MTV | Continuous | 1.030 (1.017–1.044) | NR | 1.028 (1.014–1.043) NCCN-IPI | NR |
TLG | Continuous | 1.078 (1.042–1.116) | NR | 1.071 (1.032–1.112) NCCN-IPI | NR | ||||||||
Adams [9] | 2015 | 73 | 11 | 62 | R-CHOP | Relapse: 27 Death: 24 (No defined cut-off) | 40% SUVmax | MTV | 445 ml | NS | 2.40 (1.03–5.60) | NR | NS NCCN-IPI |
TLG | 4897.5 g | NS | NS | NR | NR | ||||||||
Kim [30] | 2014 | 96 | 49 | 47 | R-CHOP | PFS3: 69.5% OS3: 72.9% (No defined cut-off) | ≥2.5 SUV | MTV | 130.7 ml | 11.2 (1.4–88.1) | NR | 10.4 (1.3–83.4) IPI >/equal to 3 NS with IPI as individual parameters | NR |
Gallicchio [25] | 2014 | 52 | 41 | 11 | R-CHOP like | Relapse: 15 Death: 2 (18 months) | 42% SUVmax | MTV | 16.1 ml | NS | NR | NR | NR |
TLG | 589.5 g | NS | NR | NR | NR | ||||||||
Sasanelli [40] | 2014 | 114 | 20 | 94 | R-CHOP/R-ACVBP | Relapse: 31 Died: 25 (3-year) | 41% SUVmax | MTV | 550 ml | 77 vs. 60% | 87% vs. 60%/59% vs. 78% vs. 84% vs. 93% | NS | 4.70 (1.82–12.18) Stage, LDH, Bulky disease 4.11 (1.67–10.16) aa-IPI, bulky disease |
TLG | 4576 g | NS | 64 vs. 85% | NR | NR | ||||||||
Esfahani [24] | 2013 | 20 | 8 | 12 | R-CHOP | Relapse: 6 Died: 0 (No defined cut-off) | 50% SUVmax | MTV | 379.2 ml | NS | N/A | NR | n/A |
TLG | 704.8 g | 11.21 (1.29–97) | N/A | NR | N/A | ||||||||
Kim [31] | 2013 | 140 | 77 | 63 | R-CHOP | Relapse: 21 Died: 16 (2-year) | 25, 50 and 75% SUVmax | TLG25 | 817.8 g | 2.8 (1.1–7.1) | NS | NR | NR |
TLG50 | 415.5 g | 3.6 (1.3–10.0) | 3.3 (1.0–10.0) | 3.6 (1.3–10.0) IPI (2 splits) | 3.1 (1.0–9.6) IPI(2 splits) | ||||||||
TLG75 | 102.0 g | 3.5 (1.3–9.5) | NS | NR | NR | ||||||||
Park [39] | 2012 | 100 | 55 | 45 | R-CHOP | NR | Blood Pool threshold | TLG | NR | NS | NR | NR | NR |
Song [44] | 2012 | 169 | 100 | 69 | R-CHOP | PFS: 73.4% OS: 76.3 (3-year) | ≥2.5 SUV | MTV | 220 ml | 5.80 (2.79–12.06) | 8.10 (3.40–19.31) | 5.30 (2.51–11.16) Stage 3 | 7.01 (2.90–16.93) Stage 3 |
HL
Author | Year | Patient no. | Stage | Treatment | Events (follow-up cut-off) | Segmentation threshold | MTV/TLG | Cut-off | Predictive univariate analysis HR (95% CI), | Predictive multivariate analysis HR (95% CI), parameters included in multivariate analysis | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
I/II | III/IV | PFS | OS | PFS | OS | ||||||||
Albano [13]a | 2020 | 123 Elderly | 36 | 87 | ABVD, BEACOPP, R-CHOP, ± RT, RT | Relapse: 51 Died: 37 (no defined cut-off) | 41% SUVmax | MTV | 89 ml | 0.531 (0.294–0.908) | NS | 0.555 (0.249–0.965) | NR |
TLG | 2199 g | 0.544 (0.240–0.963) | NS | 0.602 (0.111–0.989) | NR | ||||||||
Lue [34] | 2019 | 42 | 20 | 22 | Anthracycline-based chemotherapy ± RT | Relapse: 12 Died: 9 (5-year) | 41% SUVmax | MTV | 183 ml | 4.495 (1.434–14.09) | 4.500 (1.205–16.81) | NS | NS |
Mettler [35] | 2019 | 310 | 310 | eBEACOPP (4 or 6 cycles) | PFS: 16 events OS: 7 events (no defined cut-off) | 41% SUVmax, >2.5 SUV, Liver SUVmax, Liver SUVmean | MTV41% | NR | NS | NS | NS | NS | |
MTV2.5 | NR | NS | NS | NS | NS | ||||||||
MTVlmax | NR | NS | NS | NS | NS | ||||||||
MTVlmean | NR | NS | NS | NS | NS | ||||||||
Akhtari. [12] | 2018 | 267 | 267 | 0 | ABVD ± RT | Relapse/refractor = 27 (5-year) | ≥2.5 SUV or manually contour | MTV2.5 | Continuous | 1.00 (1.0007–1.0025) | NR | NR | NR |
TLG2.5 | 1703 g | 1.00 (1.0001–1.0004 | NR | NR | NR | ||||||||
MTVman | NR | 1.00 (1.0006–1.0019) | NR | NR | NR | ||||||||
TLGman | NR | 1.00 (1.0001–1.0004) | NR | NR | NR | ||||||||
Cottereau [21] | 2018 | 258 | 258 | ABVD ± RT | PFS: 27 events OS: 12 (5-year) | ≥2.5 SUV | MTV | 147 ml | 5.2 (1.8–14.7) | 7.2 (1.6–33.4) | Sig with individual factors, EORTC, GHCS and NCCN | Sig with individual factors, EORTC, GHCS and NCCN | |
Angelopoulou [14] | 2017 | 162 | 76 | 86 | ABVD ± BEACOPP, ± RT | PFS: 81% OS: 93% (5-year) | TLG from maximal largest diameter x SUVmax | TLG | <35, 35–100, <100 | 70 vs. 81 vs. 94% | NR | NR | NR |
Kanoun [29] | 2015 | 59 | Anthracycline-based 4–6-8 cycles | Relapse: 5 Died: 5 (no defined cut-off) | 41% SUVmax | MTV | 225 ml | 42 vs. 85% | NR | Sig when analysed with tumour change in SUVmax | NR | ||
Song. [43] | 2013 | 127 | 127 | ABVD ± RT | PFS: 85.8% OS: 88.2% (no defined cut-off) | ≥2.5 SUV | MTV | 198 ml | 10.707 (3.098–37.002) | 13.201 (2.975–58.579) | 13.008 (3.441–49.174) Age, B symptoms, mediastinal bulky disease | 15.831 (3.301–75.926 Age, B symptoms, mediastinal bulky disease | |
Tseng [46] | 2012 | 30 | 11 | 19 | Standford V, ABVD, VAMP, BEACOPP | Relapse =6 Died: 4 (4-year) | NR | MTV | NS | NS | NR | NR |
Textural and shape analysis for outcome prediction
Current limitations and future challenges
Limitation | Opportunity |
---|---|
1. Relatively small retrospective cohorts with limited events | Establishing multi-centre networks for future larger-scale studies |
2. Multiple segmentation techniques used | Consensus on segmentation technique for MTV and TLG and development of automated AI-methods which are implemented within reporting software by manufacturers |
3. Single site models using a single dataset | Internal and external validation should be routinely performed and facilitated by networks |
4. Varying predictive end points | Consensus on clinically relevant predictors |
5. Small numbers of papers using non-linear analysis | Using different machine learning and deep learning models to aid in imaging analysis and outcome prediction |